Transcription of JCOG0503
1 Japan Clinical Oncology Group 3 18-6 23-A-17 JCOG0503 II ver OVCA-oEI-PII 606-8507 54 104-0045 5-1-1 673-8558 13-70 2002 12 18 jcog PC210-DI 2005 5 1 jcog 2009 1 30 jcog 2009 7 13 jcog 7 15 2009 11 4 jcog 11 11 2011 8 16 jcog 8 22 jcog 0503 2/630.
2 / / :PS 0-2 20 75 50mg/m2/ day1-21 70mg/m2/ day1, 15 4 1 6 Primary endpoint Secondary endpoints 1 2 3 4 20 75 5 PS(ECOG) 0-2 6 RECIST CA125 70 7 8 9 10 28 11 28 14 12 1 28 6 Day 1 21 70 mg/m2 Day 1, 15 jcog 0503 3/63 60 3 1 4 6 CRF jcog jcog
